Of these eight genes, KIF2C and MYBL2 overexpression was associated with shorter OS for HCC patients, therefore, they represent potential therapeutic targets (Chen et al., 2017; Musa et al., 2017). This evidence concerns the gene MYBL2 and hepatocellular carcinoma.